According to one of the founders of BioNTech, the German company that developed the vaccine in collaboration with Pfizer, the makers of the Pfizer-BioNTech vaccine will soon ask regulators for clearance to use it in children 5 and older, and are preparing to make smaller doses of the vaccine for younger children.
“We will be presenting the results of our study on 5-to-11-year-olds to authorities all over the world in the coming weeks,” Ozlem Tureci, co-founder and chief medical officer of BioNTech, told Der Spiegel, a German news site, in an interview published on Friday. She went on to say that the company would seek approval for the vaccine’s use in that age group, including in Europe.
In May, both the European Union and the United States approved the Pfizer vaccine for use in children aged 12 and up. They haven’t approved any coronavirus vaccines for children under the age of 12.
Dr. Tureci, who co-founded BioNTech with her husband, Ugur Sahin, said the companies were preparing to produce smaller doses of the vaccine in anticipation of regulatory approval.
Dr. Sahin, the CEO of BioNTech, urged anyone who is eligible for vaccination to get their shots before an expected wave of infections this fall.
“We still have about 60 days as a society to avoid a harsh winter,” he said.